New Combination Therapy Improves Outcomes in High-Risk Leukemia

New combination therapy improves outcomes in high-risk leukemia

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment outcomes and survival in patients with acute myeloid leukaemia (AML) with FLT3 gene mutations.

HKUMed Pioneers Innovative Combination Therapy to Lower Leukemia Relapse

A groundbreaking therapeutic strategy has emerged from the Department of Medicine at the School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong (HKUMed), promising to reshape the treatment landscape for acute myeloid leukemia (AML) patients harboring FLT3 gene mutations. This novel combination therapy, designated QUIZOM, pairs the potent FLT3 inhibitor Quizartinib with the protein synthesis inhibitor Omacetaxine Mepesuccin…